Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15699370 | 1.00 | CTSK (0.48) | CTSKPPARAMAPTKLK7KLK5 | |
| SCHEMBL952620 | 1.00 | CTSK (0.48) | CTSKPPARAMAPTKLK7KLK5 | |
| SCHEMBL31028252 | 0.92 | CTSK (0.47) | CTSKPPARAMAPTCTSS | |
| SCHEMBL955905 | 0.87 | ALDH1A1 (0.48) | CTSKPPARACTSS | |
| SCHEMBL28821322 | 0.87 | ALDH1A1 (0.48) | CTSKPPARACTSS | |
| SCHEMBL955903 | 0.87 | ALDH1A1 (0.48) | CTSKPPARACTSS | |
| SCHEMBL20562065 | 0.84 | ALDH1A1 (0.50) | CTSKPPARACTSS | |
| SCHEMBL20562067 | 0.84 | ALDH1A1 (0.50) | CTSKPPARACTSS | |
| SCHEMBL13561434 | 0.83 | HDAC1 (0.53) | — | |
| SCHEMBL31526993 | 0.83 | KLK5 (0.46) | CTSKPPARAKLK5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-9278997-B2 | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20120277406-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277406-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, PTMS | CTSK 1094/4885PPARA 4324/4885MAPT 2566/4885 |
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, PTMS | CTSK 1094/4885PPARA 4324/4885MAPT 2566/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | CTSK 1809/4885PPARA 750/4885MAPT 4867/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | CTSK 2016/4885PPARA 387/4885MAPT 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.